옵션 체인은 다양한 행사가격과 만기일에 대한 INVO Fertility의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 INVO Fertility에 대한 시장 심리를 평가합니다..

INVO Fertility (NASDAQ:NAYA) 주식, 옵션 체인

NAYA Biosciences

INVO Bioscience

INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body.

INVO Fertility Inc

Nayax Ltd

Baird analyst Ben Kallo maintains QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) with a Neutral and lowers the price target from $8 to $6.

News

Price Target

Analyst Ratings

Baird Maintains Neutral on QuantumScape, Lowers Price Target to $6

Ladder Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LADR#NYSE">LADR</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.22 by 9.09 percent. This is a 39.39 percent decrease over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $51.20 million which missed the analyst consensus estimate of $65.35 million by 21.65 percent. This is a 25.79 percent decrease over sales of $69.00 million the same period last year.

Earnings

Earnings Misses

LADR

Ladder Cap Q1 Adj. EPS $0.20 Misses $0.22 Estimate, Sales $51.20M Miss $65.35M Estimate

WIIM

ALLE

ALLE stock has given up its prior loss. Allegion shares were trading lower after the company reported Q1 financial results and issued FY25 EPS guidance below estimates.

Macro Economic Events

Econ #s

Economics

USA Durables Excluding Defense (MoM) For March 10.4% Vs 0.2% Est.; 0.8% Prior

USA Continuing Jobless Claims 1,841K Vs 1,880K Est: 1,878K Prior

Baird analyst Timothy Wojs maintains Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) with a Neutral and lowers the price target from $608 to $600.

Baird Maintains Neutral on Lennox Intl, Lowers Price Target to $600

Macro Notification

General

US Initial Jobless Claims 222K vs 222K Est.; Prior 216K

Core Durable Goods Orders MoM For March 0.0% Vs 0.3% Expected; 0.7% Prior

USA Durable Goods Orders (MoM) For March 9.2% Vs 2.1% Est.; 0.9% Prior

PEP stock has given up its prior loss. PepsiCo shares were trading lower after the company reported mixed Q1 results and issued FY25 EPS guidance below estimates. The company indicated it sees more volatility and uncertainty related to trade, which it expects to increase supply chain costs.

Baird analyst Ben Kallo maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $387 to $405.

Baird Maintains Outperform on GE Vernova, Raises Price Target to $405

Baird analyst Timothy Wojs maintains Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) with a Outperform and raises the price target from $455 to $460.

Baird Maintains Outperform on Carlisle Companies, Raises Price Target to $460

Baird analyst Ghansham Panjabi maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Outperform and lowers the price target from $220 to $210.

Baird Maintains Outperform on Avery Dennison, Lowers Price Target to $210

Baird analyst Luke Junk maintains Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) with a Outperform and raises the price target from $73 to $85.

Baird Maintains Outperform on Amphenol, Raises Price Target to $85

Baird analyst Catherine Schulte maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $603 to $573.

Baird Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $573

Canaccord Genuity analyst Joseph Vafi maintains Galaxy Digital Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#TSX">GLXY</a>) with a Buy and raises the price target from C$37 to C$41.

TSX:GLXY

Canaccord Genuity Maintains Buy on Galaxy Digital Holdings, Raises Price Target to C$41

Presentation to Highlight Genprex's Study of Reqorsa Gene Therapy in Combination with Tecentriq&#xAE; for the Treatment of Extensive Stage Small Cell Lung Cancer
AUSTIN, Texas, April 24, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4410514-1&amp;h=3739601814&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been selected to present at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois and online. Genprex's abstract was selected for a poster presentation for the Trials in Progress portion of the conference. The Company will present the trial design of the Acclaim-3 Phase 1/2 clinical trial evaluating Genprex's lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid), in combination with Tecentriq&#xAE; as maintenance therapy for the treatment of extensive stage small cell lung cancer (ES-SCLC).

Biotech

Penny Stocks

GNPX

Genprex Selected To Present Trial Design Of Acclaim-3 Clinical Trial Evaluating Reqorsa Gene Therapy In Small Cell Lung Cancer At 2025 ASCO Annual Meeting

Warnings of empty shelves and financial chaos pushed President Donald Trump to soften his fight with the Federal Reserve and cool talk of a deeper tariff war with China, lifting Wall Street out of a tailspin late Wednesday.
What Happened: The about-face came after top retailers — Walmart, Target, Home Depot, and Lowe's — met Trump in the Oval Office and bluntly cautioned that his trade fight was tightening supply lines. According to a CNN <a href="https://edition.cnn.com/2025/04/23/business/stock-market-dow-jerome-powell-fed-trump/index.html">report</a>, one executive told him store shelves could "soon be empty," according to people familiar with the discussion. Earlier alarms from advisers and major CEOs had underscored the risk of firing Fed Chair Jerome Powell and escalating tariffs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: CNN is reporting that on Monday Trump met with CEOs of Lowes, Target, Walmart and Home Depot, who told him that his Tariffs were going to cause &quot;Empty Shelves&quot; in their stores as early as this summer. Businesses are panicking, and that&#39;s why he took a softer tone last… <a href="https://t.co/W7RdCoCt6E">pic.twitter.com/W7RdCoCt6E</a>
&mdash; Ed Krassenstein (@EdKrassen) <a href="https://twitter.com/EdKrassen/status/1915137091563917717?ref_src=twsrc%5Etfw">April 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Hours later, Trump reversed course. "I have no intention of firing him," he said of Powell, a remark that sent the Dow (INDEXDJX: .DJI) up as much as 1,200 points before it settled 420 points higher. The S&amp;P 500 (INDEXSP: .INX) rose 1.67 percent and the Nasdaq (INDEXNASDAQ: .IXIC) gained 2.5 percent, though all three indexes finished below intraday peaks after Treasury Secretary Scott Bessent warned that rebalancing trade could take a "2 to 3-year timeline."
See also: <a href="https://www.benzinga.com/news/25/04/44975014/tim-walz-slams-trump-as-a-man-who-wants-to-be-a-king-in-blistering-state-of-the-state-address">Tim Walz Slams Trump Over Tariffs, DOGE Department In Blistering Speech, Calls Him A &#8216;Man Who Wants To Be A King&#8217;</a>
Stocks rallied again when Bessent <a href="https://www.benzinga.com/markets/equities/25/04/44970416/scott-bessents-china-de-escalation-scoop-delivered-to-wall-street-early-at-closed-door-event-2-2-trillion-in-gains-later-questions-arise-if-retail-investors-were">hinted at de-escalation</a> with Beijing, yet the administration kept its bargaining chip. White House press secretary Karoline Leavitt insisted there would be "no unilateral reduction in tariffs against China."
Trump told reporters negotiations with China and others remain "active. Everything's active." For jittery CEOs, the president's new tone offered breathing room. But until a clear trade deal lands, they warned, shelves — and markets — could still run dangerously low on comfort.
Why It Matters: China's Ministry of Commerce <a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis">rejected reports</a> that Beijing is quietly negotiating with Washington, calling talk of active trade discussions "unfounded." The denial follows U.S. Treasury Secretary Scott Bessent's remarks at a closed-door JPMorgan investor summit, where he called the current tariff levels "unsustainable" and predicted a "de-escalation" in U.S.–China duties.
The rumor mill spun faster after President Donald Trump said earlier this week that he might revisit the "high tariffs" imposed during his second term and that senior Chinese officials had reached out to explore talks. Trump has since promised a <a href="https://www.benzinga.com/markets/25/04/44942449/trump-pledges-substantial-cut-in-china-tariffs-but-refuses-to-make-it-zero-if-they-dont-make-a-deal-we-will-set-the-deal">sizable cut</a> to those duties, while insisting they will not be scrapped entirely. Beijing's swift dismissal highlights the lingering tension — and uncertainty — clouding the tariff standoff.
Read next: <a href="https://www.benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Says Tariffs Could Replace Income Tax: Experts Warn The Math Doesn't Work</a>

Government

Regulations

Politics

IXIC

Trump Backs Off Firing Powell After Walmart, Target CEOs Warn Him Of Empty Store Shelves

Management

GPRK

GeoPark Appoints Felipe Bayon As CEO, Effective June 1, 2025

Tigress Financial analyst Ivan Feinseth maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Buy and raises the price target from $27 to $28.

Tigress Financial Maintains Buy on Albertsons Companies, Raises Price Target to $28

Press Releases

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

NAYA Biosciences Announces Nomination of New Board Members

NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed "INVO Fertility, Inc."

Comments

INVO Fertility

INVO Fertility (NAYA) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌